OM336 in Autoimmune Cytopenias

Part of paid clinical trials in Duarte, California.

Sponsor
Lakefront Biotherapeutics West LLC
Study ID
NCT07083960
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • AIHA - Cold Autoimmune Hemolytic Anemia
  • AIHA - Warm Autoimmune Hemolytic Anemia
  • ITP - Immune Thrombocytopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • OM336 — DRUG
    OM336 is an engineered bispecific antibody directed against BCMA and CD3

Study Details

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Key Dates

First listed
Jul 24, 2025
Start date
Aug 1, 2025
Status verified
Sep 2026
Primary completion
Dec 31, 2026
Completion
Sep 30, 2027

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: OM336 Dose Escalation
    Participants will receive OM336 via subcutaneous injection in ascending dose cohorts

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 12 weeks ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Primary Contact
[email protected]
(888) 734-0917
MedstarWashington D.C.District of Columbia20007
Primary Contact
[email protected]
202-444-2000
University of MichiganAnn ArborMichigan48109
Primary Contact
[email protected]
734-764-1817
Fred Hutchinson Cancer CenterSeattleWashington98109
Primary Contact
[email protected]
855-557-0555

Find similar trials in Duarte, CA

By research site
City of Hope· Duarte, CAMedstar· Washington D.C., DCUniversity of Michigan· Ann Arbor, MIFred Hutchinson Cancer Center· Seattle, WA

Related Studies